Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status

Faeth Therapeutics is conducting a Phase II trial, Study FTH-PIK-201, in second-line advanced endometrial cancer. Credit: Jo Panuwat D / Shutterstock.com.